Table 1 Animal model and in vitro surveys of IL-33 allergic diseases
Model of study | Result | Ref |
|---|---|---|
OVA-sensitized mice received ovalbumin solution and were fed with capsaicin | -Not reduce production of IgE and weight loss -Reduced macrophage infiltration and IL-33 in the proximal jejunum -Reduced hepatic triglycerides and intestinal hydroperoxides | [150] |
intra-lymphatic injection of OVA-flagellin (FlaB) mixture in the murine AR | -Reduce the production of IL-33 -Ameliorate allergic inflammation | [151] |
ST2 and IL-33 in OVA-induced airway inflammation in mice | -Increased of sST2 and IL-33 are in the serum -Increased of sST2 and IL-33 are in the lung -Expressed of IL-33 in alveolar macrophages, CD11c + cells, and epithelial cells in the lungs | |
transgenic overexpression or fed of IL-33 In mouse models | -Generates airway eosinophilia -Upregulates Th2 cytokine expression -Elevates serum IgE, AHR, and mucus secretion | |
preventative use of an mIL-33 during OVA-induced asthma | -Modulated pulmonary inflammation -Decrease Th2 cytokine production | [154] |
anti-ST2 antibody (clone E310), anti- IL-33 Ab, or soluble ST2-Fc fusion protein investigate role of the ST2/ IL-33 in asthma models | - Inhibits airway inflammation - Inhibits the Th2-associated responses - Reduced IgE level in serum - Reduced the numbers of eosinophils in BALF | |
role of anti-IL-33 and sST2 in the blockade of airway inflammation in a murine model of asthma | - Reducing the total cell count - Serve as therapeutic agents for allergic asthma | [44] |
experimental murine of severe airway inflammation and administered IL-33 neutralizing Ab | - Improved both airway remodeling - Improved inflammation improved, - IL-33 blockade decreases asthmatic exacerbations | [157] |
Anti-mouse IL-33 antibody treatment in AD | - Improvement of AD symptoms - Reduction of cells (EOS and mast cells) - Reduction of serum IgE levels | |
Anti–IL-33 treatments in a mouse model of allergic rhinitis | -Reduced nose-scratching events -Ameliorated skin denudation -Decreased eosinophilic infiltration -Decreased levels of serum total and IgE | [109] |
Topical tacrolimus treatment of mouse AD | -Decreases expression of IL-33 -Decrease expression of ST2 in | [75] |
IL-33 in a model of acute allergic airway inflammation (IL-33 KO mice) | -Demonstrate that IL-33 role in production of Th2 cytokines -Demonstrate EOS infiltrates to lung -Demonstrate histopathologic changes in the lung | [64] |
mechanisms of IL-2 production from MCs in chronic allergic dermatitis in response to IL-33 | - Further IL-2 production by binding FcεRI -IL-2 led to considerable expansion of Tregs - Increased numbers of IL-2 expressing MCs | [159] |
IL-33 and ST2 receptor in allergic airway inflammation mice | -Elevated levels of soluble ST2 in the serum | |
Mice treated with anti-IL-33-neutralizing Ab in OVA-induced AR | -Reduced eosinophilia during -Suggesting the role of IL-33 in the disease development | [109] |
mAbs to IL-25, IL-33, and TSLP cytokines in food allergy mice | - Strongly inhibited FA development - FA suppression required treatment with a cocktail of all three mAbs - Treatment 3-mAb cocktail during induced FA tolerance. | [122] |
IL-33 used in wildtype mice after exposure to Alternaria alternata allergen | - Increase airway eosinophilia - Increase bone marrow eosinophilopoies - Activation of ILC2 and their production of IL-5 | |
IL-33 in ova induced asthma model in mice | -Induces eosinophil-mediated massive airway inflammation of the lung tissue -Elevated local concentrations of IL-5, IL-13 -Induced goblet cell hyperplasia | [163] |
Repeated systemic administration of recombinant IL-33 | -Induces eosinophilia splenomegaly -Production of Th2 cytokines -Increased IgE serum levels |